

New cascade transformations of 3-(2-aminophenylamino)-5,5-dimethyl-2-cyclohexen-1-one

Lev Yu. Ukhin,^{*a} Kyrill Yu. Suponitsky,^b Eugenii N. Shepelenko,^c
Lyudmila V. Belousova,^{*a} Oxana S. Popova^a and Gennadii S. Borodkin^a

^a Institute of Physical and Organic Chemistry, Southern Federal University, 344090 Rostov-on-Don, Russian Federation. Fax: +7 863 243 4700; e-mail: may@ipoc.sfedu.ru

^b A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation

^c Southern Scientific Center of the Russian Academy of Sciences, 344006 Rostov-on-Don, Russian Federation

DOI: 10.1016/j.mencom.2015.03.020

The reaction of 3-(2-aminophenylamino)-5,5-dimethyl-2-cyclohexen-1-one with alloxan results in 3,3-dimethyl-1,2,3,4,10,11-hexahydrospiro(1*H*-dibenzo[*b,e*][1,4]diazepine)-11,5'-pyrimidine-1,2',4',6'-tetraone or *N*-aminocarbonyl-1-(2-aminophenyl)-3-hydroxy-6,6-dimethyl-2,4-dioxo-2,3,4,5,6,7-hexahydro-1*H*-indole-3-carboxamide. The latter undergoes isomerization on dissolution in DMSO or DMF to give 5-[2-(2-aminophenylamino)-4,4-dimethyl-6-oxocyclohexenyl]-5-hydroxypyrimidine-2,4,6(1*H*,3*H*,6*H*)-trione, thus demonstrating a new example of ring–ring tautomerism.

3-(2-Aminophenylamino)-5,5-dimethyl-2-cyclohexen-1-one **1** is a valuable compound in synthetic and medicinal chemistry.^{1–3} Its reactions with isatins give spiro derivatives incorporating dibenzodiazepinone and oxindole moieties.⁴ The reaction of compound **1** with 2,6-di-*tert*-butyl-1,4-benzoquinone affords phenazine derivative with a 4,6-di-*tert*-butylphenol substituent,^{5,6} while those with 3,5-di-*tert*-butyl-1,2-benzoquinone or 1,2-naphthoquinone lead to nine-membered macrolactones.^{7,8} A common feature of all these processes is that cyclization involves the free amino group of compound **1**.

In the present study, we found that short refluxing of equimolar amounts of **1** and alloxan **2** in EtOH containing a catalytic

amount of CF₃COOH gave hitherto unknown *N*-aminocarbonyl-1-(2-aminophenyl)-3-hydroxy-6,6-dimethyl-2,4-dioxo-2,3,4,5,6,7-hexahydro-1*H*-indole-3-carboxamide **3** (Scheme 1).[†] In other


[†] Spectral studies were carried out using the equipment of the User Facilities Center ‘Molecular Spectroscopy’ at the Southern Federal University.

N-Aminocarbonyl-1-(2-aminophenyl)-3-hydroxy-6,6-dimethyl-2,4-dioxo-2,3,4,5,6,7-hexahydro-1*H*-indole-3-carboxamide **3**. A mixture of compound **1** (0.46 g, 2 mmol), compound **2** (0.38 g, 2 mmol), EtOH (10 ml) and 2 drops of CF₃COOH was refluxed until dissolution (1–2 min), cooled with rubbing by a glass rod, and kept for 1 h in ice. The precipitate was filtered off, then washed with EtOH and light petroleum. The yield of the crude product was 0.5 g (67%). A colourless compound, mp 175–182 °C (decomp.) (Pr^oH). IR (ν /cm⁻¹): 3463, 3380, 3350, 3300, 3200, 3098 (OH, NH), 1761, 1726, 1686, 1690 (CO), 1531, 1502 (arom.). MS, *m/z*: 372 [M]⁺. The NMR spectra of compound **3** in DMSO-*d*₆ or DMF-*d*₇ match those of isomeric compound **5**.

3,3-Dimethyl-2,3,4,5,10,11-hexahydrospiro(1*H*-dibenzo[*b,e*][1,4]-diazepine)-11,5'-pyrimidine-1,2',4',6'-tetraone **4**.

(A) A mixture of compound **1** (0.23 g, 1 mmol) and compound **2** (0.19 g, 1 mmol) was refluxed for 1–2 min with CF₃COOH (2.5 ml). After cooling, diethyl ether (7 ml) was added to the orange solution and the mixture was cooled on ice. The precipitate was filtered off and washed with diethyl ether. The yield of the crude product was 0.25 g (70%). To obtain the pure compound, the reaction product was recrystallized from methanol. Colourless crystals were formed that gradually darken above 310 °C and decompose with intense gas evolution at 322 °C.


(B) A mixture of compound **3** (0.1 g, 0.27 mmol) and CF₃COOH (0.3 ml) was heated to boiling. The yellowish-red mixture was cooled, then diethyl ether (5 ml) was added. The precipitate was filtered off and washed with Et₂O. The yield of the crude product was 0.082 g (86%). A colourless compound, mp 322 °C (decomp.) (methanol). IR (ν /cm⁻¹): 3325, 3256, 3193, 3149, 3074 (NH), 1736, 1719, 1698 (CO), 1635, 1599, 1578, 1536 (arom.). ¹H NMR (DMSO-*d*₆) δ : 1.06 (s, 6H, Me), 1.99 [s, 2H, C(2)H₂], 2.57 [s, 2H, C(4)H₂], 6.28 [s, 1H, N(10)H], 6.83 [m, 2H, C(7)H, C(8)H], 6.92 [m, 1H, C(9)H], 7.04 [m, 1H, C(6)H], 9.04 [s, 1H, N(5)H], 10.99 [s, 2H, N(1')H, N(3')H]. ¹³C NMR (DMSO-*d*₆) δ : 27.45 [C(12)], C(12a)], 31.34 [C(3)], 44.46 [C(4)], 48.76 [C(2)], 65.72 [C(11)], 106.44 [C(11a)], 120.16 [C(6)], 121.44 [C(7)], 121.48 [C(9)], 123.41 [C(8)], 132.93 [C(5a)], 135.57 [C(9a)], 150.44 [C(2')], 155.16 [C(4a)], 169.43 [C(4')], 169.43 [C(6')], 194.67 [C(1)]. ¹⁵N NMR (DMSO-*d*₆) δ : 72.50 [N(10)], 120.00 [N(5)], 147.90 [N(1')], 147.90 [N(3')]. MS, *m/z*: 354 [M]⁺ (100%). Found (%): C, 61.08; H, 5.32. Calc. for C₁₈H₁₈N₄O₄ (%): C, 61.01; H, 5.12.



Scheme 1

words, [3+2]-cycloaddition recently reported for **1** analogues⁸ involving no amino group occurs in this case. The similar processing in CF₃COOH resulted in 3,3-dimethyl-1,2,3,4,10,11-hexahydrospiro(1*H*-dibenzo[*b,e*][1,4]diazepine)-11,5'-pyrimidine-1,2',4',6'-tetraone **4**. Here, like in the reactions of **1** with isatins,⁴ the amino group is incorporated in the diazepine ring. Finally, we found that compound **3** underwent conversion to compound **4** upon dissolution in CF₃COOH under reflux conditions. On dissolution in DMSO or DMF, compound **3** isomerized to pyrimidine-2,4,6(1*H*,3*H*,6*H*)-trione derivative **5**, which on heating in CF₃COOH yielded the same spiro product **4**.

The possible formation mechanism of compound **3** is presented in Scheme 2. Under conditions of acid catalysis, the reaction starts with elimination of one hydroxy group from alloxan. The resulting carbocation attacks the enamine moiety of molecule **1**. This is followed by cyclization with opening of the alloxan ring and retention of the second hydroxy group and amino group.



Scheme 2

The structure of compound **3** was proved by X-ray diffraction analysis (Figure 1).[‡] The stoichiometry was confirmed by the mass spectrum and elemental analysis. However, the number of signals in the ¹³C and ¹⁵N NMR spectra recorded in DMSO-*d*₆ did not match the expected values. The N(1) nitrogen manifested itself as NH and correlated with C(7)H₂ and C(6')H protons.

5-[2-(2-Aminophenylamino)-4,4-dimethyl-6-oxocyclohexenyl]-5-hydroxypyrimidine-2,4,6(1*H*,3*H*,6*H*)-trione · *n*(Me)₂SO **5**. A mixture of compound **3** (0.1 g, 0.27 mmol) and DMSO (0.25 ml) was slightly heated over a heating stage. Crystallization started right after dissolution. The mixture was cooled, then Pr'OH (1 ml) and diethyl ether (2 ml) were added. The mixture was cooled with ice while rubbing with a glass rod. The precipitate was filtered off, washed with Et₂O and light petroleum and dried. The yield of a colourless compound was 0.12 g, mp 140–150 °C (decomp.). IR (ν /cm⁻¹): 3441, 3326, 3287, 3212, 3005 (OH, NH), 1740, 1715, 1697 (CO), 1636, 1597, 1542, 1501 (arom.), 1009 (S=O). ¹H NMR (DMSO-*d*₆) δ : 1.98 [s, 2H, C(5')H₂], 2.16 [s, 2H, C(3')H₂], 5.13 [s, 2H, NH₂], 6.57 [t, 1H, C(4'')H, *J* 7.8 Hz], 6.75 [d, 1H, C(3'')H, *J* 7.2 Hz], 7.02 [d, 1H, C(6'')H, *J* 7.5 Hz], 7.04 [t, 1H, C(5'')H, *J* 7.8 Hz], 7.94 [s, 1H, OH], 9.19 [s, 1H, N(7)H], 11.10 [s, 2H, N(1)H, N(3)H]. In the ¹H NMR spectrum of solvate **5** recorded in DMF-*d*₇, the 'compound : DMSO' ratio is 1 : 1.62, while according to elemental analysis this ratio is 1 : 1.8. The analysis results match the C_{21.6}H_{30.8}N₄S_{1.8}O₆ stoichiometry. ¹³C NMR (DMSO-*d*₆) δ : 31.97 [C(4')], 39.96 [C(3')], 48.91 [C(5')], 65.72 [C(5)], 106.02 [C(1'')], 114.89 [C(3'')], 116.02 [C(4'')], 128.09 [C(5'')], 128.28 [C(6'')], 150.44 [C(2)], 171.09 [C(4)], 171.09 [C(6)], 192.82 [C(6')]. ¹⁵N NMR (DMSO-*d*₆) δ : 55.80 (NH₂), 106.70 [N(7)], 147.30 [N(1)], 147.30 [N(3)]. Found (%): C, 50.55; H, 5.88; S, 11.11. Calc. for C_{21.6}H_{30.8}N₄S_{1.8}O₆ (%): C, 50.57; H, 6.05; S, 11.25.





Figure 1 General view of molecule **3** with the atoms presented as atom vibration ellipsoids at 50% probability.

Total assignment of signals in ¹H NMR spectra was performed using the COSY pulse correlation sequence for ¹³C NMR HMBC and HSQC spectra, and HMBC for ¹⁵N NMR spectra (see Online Supplementary Materials). The combination of these data indicates that compound **3** undergoes isomerization to pyrimidine-2,4,6(1*H*,3*H*,6*H*)-trione **5** on dissolution in DMSO (Scheme 3).



Scheme 3

Compound **5** was isolated as a crystal solvate with DMSO. The ¹H NMR spectrum of solvate **5** recorded in DMF-*d*₇ gives the 'compound : DMSO' ratio of 1 : 1.62, whereas elemental analysis provides 1 : 1.8. A very intense band of stretching vibrations ν_{SO} 1009 cm⁻¹ is observed in the IR spectrum of the solvate. Compound **3** undergoes a similar rearrangement in DMF, but we failed to isolate the corresponding solvate. The behaviour of compound **3** in aprotic bipolar solvents is a new example of ring–ring tautomerism.⁹


We assume that the driving force of the isomerization **3** → **5** is provided by specific solvation of the carbamoyl amino group in compound **3** by DMSO ($\epsilon = 49$)¹⁰ or DMF ($\epsilon = 36.7$)¹⁰ that facilitates a nucleophilic attack on the C(2) carbon (see Scheme 3). The presence of DMSO or DMF is apparently a prerequisite

[‡] Crystal data for **3**. C₁₈H₂₀N₄O₅ · 0.375 C₂H₆O · 0.25 H₂O, triclinic, space group *P* $\bar{1}$, *a* = 9.4539(8), *b* = 10.1566(9) and *c* = 23.038(2) Å, α = 79.712(2)°, β = 85.517(2)°, γ = 65.596(2)°, *V* = 1982.0(3) Å³, *Z* = 4, *M* = 394.16, *d*_{calc} = 1.321 g cm⁻³, *wR*₂ = 0.1530 calculated on *F*_{hkl}² for 8611 independent reflections with $2\theta < 54^\circ$ [GOF = 1.045, *R* = 0.0618 calculated on *F*_{hkl} for 4676 reflections with *I* > 2 σ (*I*)].

Crystal data for **4**. C₁₈H₁₈N₄O₄ · 2MeOH, 120 K, monoclinic, space group *P*2₁/*c*, *a* = 10.047(6), *b* = 20.773(12) and *c* = 10.292(6) Å, β = 99.116(7)°, *V* = 2121(2) Å³, *Z* = 4, *M* = 418.45, *d*_{calc} = 1.311 g cm⁻³, *wR*₂ = 0.2196 calculated on *F*_{hkl}² for 8163 independent reflections with $2\theta < 52^\circ$ [GOF = 0.971, *R* = 0.0753 calculated on *F*_{hkl} for 1361 reflections with *I* > 2 σ (*I*)].

CCDC 978821 and 992437 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <http://www.ccdc.cam.ac.uk>.

For details, see Online Supplementary Materials.




Scheme 4

of the occurrence of structure **5**. On recrystallization of solvate **5** from MeCN, it isomerizes back into compound **3**. We included an intermediate similar to **5** in the assumed scheme of the formation of compound **3** (Scheme 2).

A review⁸ of ¹³C NMR spectra (DMSO-*d*₆) of analogues of compound **3** leads us to the conclusion that they also undergo isomerization to analogues of compound **5**.

A possible mechanism of the reaction between compounds **1** and **2** in CF₃COOH under reflux conditions involves consecutive elimination of both hydroxy groups and incorporation of the amino group in the diazepine ring (Scheme 4), as it occurs in reactions of **1** with isatins.⁴

The first step of the **3** → **4** conversion in CF₃COOH may also involve elimination of a hydroxy group to afford carbocation **6**, which is then rearranged to compound **4**. However, an alternative route is also possible, namely, protonation of indole nitrogen, indole ring cleavage and alloxan ring closure, followed by hydration to give compound **4** (Scheme 5).



Scheme 5




Figure 2 General view of molecule **4** with the atoms presented as atom vibration ellipsoids at 50% probability.

Compound **4** has high thermal stability; it does not change on heating to 310 °C. Molecule **4** demonstrates high resistance to electron impact. The relative intensity of the molecular ion signal in the mass spectrum recorded at an ionization energy of 70 eV is 100%. The structure of compound **4** was confirmed by X-ray diffraction analysis (Figure 2).[‡]

This study was carried out in accordance with task no. 4.196.2014/K in the framework of the project part of the state task on scientific activity of Southern Federal University.

We dedicate this study to the memory of **Zhanna I. Orlova**, who was our colleague and co-author for many years.

Online Supplementary Materials

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.mencom.2015.03.020.

References

- 1 S. Miano and N. Abe, *Chem. Pharm. Bull.*, 1972, **20**, 1588.
- 2 L. Yu. Ukhin, K. Yu. Suponitskii, E. N. Shepelenko, L. V. Belousova, Zh. I. Orlova and G. S. Borodkin, *Russ. Chem. Bull., Int. Ed.*, 2011, **60**, 1729 (*Izv. Akad. Nauk, Ser. Khim.*, 2011, 1703).
- 3 J.-F. Bonfanti, F. M. M. Doublet, O. Nyanguile, P. J.-M. B. Raboisson, A.-S. H. M. Rebstock and C. W. M. Boutton, *WO Patent 2007026024A2*, 2007 (*Chem. Abstr.*, 2007, **146**, 316950).
- 4 Zh. I. Orlova, L. Yu. Ukhin, K. Yu. Suponitskii, E. N. Shepelenko, L. V. Belousova, G. S. Borodkin and O. S. Popova, *Russ. Chem. Bull., Int. Ed.*, 2013, **62**, 1409 (*Izv. Akad. Nauk, Ser. Khim.*, 2013, 1409).
- 5 L. Yu. Ukhin, K. Yu. Suponitskii, E. N. Shepelenko, L. V. Belousova and G. S. Borodkin, *Abstracts of VI International Conference 'High-Spin Molecular Magnets'*, Rostov-on-Don, 2012, p. 149.
- 6 L. Yu. Ukhin, Zh. I. Orlova, K. Yu. Suponitsky, E. N. Shepelenko and L. V. Belousova, *Mendeleev Commun.*, 2014, **24**, 233.
- 7 L. Yu. Ukhin, K. Yu. Suponitskii, E. N. Shepelenko, L. V. Belousova and G. S. Borodkin, *Tetrahedron Lett.*, 2012, **53**, 67.
- 8 L.-Yu. Xue, B. Jiang, M.-S. Tu and Sh.-J. Tu, *Tetrahedron Lett.*, 2012, **53**, 6611.
- 9 V. V. Alekseyev, S. I. Yakimovich, I. V. Zerova, M. B. Egorova and J. Sinkkonen, *Chem. Heterocycl. Compd.*, 2014, **49**, 1490 (*Khim. Geterotsikl. Soedin.*, 2013, 1606).
- 10 A. J. Gordon and R. A. Ford, *The Chemist's Companion: A Handbook of Practical Data, Techniques, and References*, Wiley-Interscience, New York, 1972.

Received: 27th June 2014; Com. 14/4408